Bristol-Myers Squibb Co
NYSE:BMY
Bristol-Myers Squibb Co
NYSE:BMY
Price:
48.78 USD
-0.43%
Updated:
Apr 24, 2024
Bristol-Myers Squibb Co
Operating Income
Last
Value
3-Years CAGR
5-Years CAGR
|
Bristol-Myers Squibb Co
Operating Income Peer Comparison
Comparables:
JNJ
PFE
MRK
ZTS
LLY
Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Operating Income
$10.8B
|
CAGR 3-Years
22%
|
CAGR 5-Years
7%
|
CAGR 10-Years
13%
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Operating Income
$23.4B
|
CAGR 3-Years
3%
|
CAGR 5-Years
3%
|
CAGR 10-Years
3%
|
|
|
Pfizer Inc
NYSE:PFE
|
Operating Income
$13.1B
|
CAGR 3-Years
4%
|
CAGR 5-Years
8%
|
CAGR 10-Years
-3%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Operating Income
$4.1B
|
CAGR 3-Years
-28%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
-7%
|
|
|
Zoetis Inc
NYSE:ZTS
|
Operating Income
$3.1B
|
CAGR 3-Years
11%
|
CAGR 5-Years
10%
|
CAGR 10-Years
14%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Operating Income
$10.3B
|
CAGR 3-Years
15%
|
CAGR 5-Years
12%
|
CAGR 10-Years
6%
|
See Also
What is Bristol-Myers Squibb Co's Operating Income?
Operating Income
10.8B
USD
10.8B
USD
Based on the financial report for Dec 31, 2023, Bristol-Myers Squibb Co's Operating Income amounts to 10.8B USD.
What is Bristol-Myers Squibb Co's Operating Income growth rate?
Operating Income CAGR 10Y
13%
13%
Over the last year, the Operating Income growth was -5%. The average annual Operating Income growth rates for Bristol-Myers Squibb Co have been 22% over the past three years , 7% over the past five years , and 13% over the past ten years .
You don't have any saved screeners yet
